Govt warns: Sale of weight loss drug generics only on doctor’s prescription, Pg4

Key Highlights:

• CDSCO issued an advisory regarding the sale of semaglutide generics.
• Semaglutide generics must be sold only with a registered medical practitioner's prescription.
• Promotion of semaglutide to the general public is prohibited by CDSCO.

Detailed Insights:

• The advisory was issued ahead of the launch of generic versions of the GLP-1 drug semaglutide.
• CDSCO considers promotion that induces demand or exaggerates efficacy as misleading.
• The advisory addresses concerns about pharmaceutical companies' promotional activities for GLP-1 receptor agonists.
• CDSCO views promotional activities, including awareness campaigns, as surrogate advertisements.
• Such activities may be treated as irrational or misleading marketing practices.

Key Concepts Involved:

• Semaglutide: A GLP-1 drug used for treating obesity and metabolic disorders.
• GLP-1 Receptor Agonists: A class of drugs that mimic the effects of GLP-1 to lower blood sugar levels.
• CDSCO: National regulatory body for pharmaceuticals and medical devices in India.